Drug Trial Radar · NCT01579565
Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
Last checked: Nov 20, 2026Latest source record: Jun 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
416
Actual
Start
Apr 2012
Primary completion
Nov 2012
Study completion Jan 2013
Sponsor
- Lead sponsor
- Omeros CorporationIndustry
- Sponsor type
- Industry
- First posted
- Apr 18, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, efficacy and pharmacokinetics of OMS302 (the study drug) for maintaining intraoperative mydriasis and preventing post operative pain in individuals undergoing Intraocular Lens Replacement (ILR) surgery.
Conditions
- Intraocular Lens Replacement
Interventions
OMS302Drug
OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
PlaceboDrug
Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Area Under the Curve Analysis of Change-from-Baseline in Pupil Diameter (mm) During SurgeryTime frame: From surgery baseline (pre-incision) through surgery end (time of cortical clean-up/wound closure)
- Mean Area Under the Curve Analysis of Ocular Pain VAS Score Within 12 Hours PostoperativelyTime frame: 12 hours postoperatively
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Chandler, Arizona
Site not named
Los Angeles, California
Site not named
Fort Myers, Florida
Site not named
Boston, Massachusetts
Site not named
St Louis, Missouri
Site not named
Washington, Missouri
Site not named
Albuquerque, New Mexico
Site not named
New York, New York
Site not named
Goodlettsville, Tennessee
Site not named
Austin, Texas
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Salt Lake City, Utah
Site not named
Zwolle, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.